WO2022127894A1 - 除草剂抗性植物 - Google Patents
除草剂抗性植物 Download PDFInfo
- Publication number
- WO2022127894A1 WO2022127894A1 PCT/CN2021/139052 CN2021139052W WO2022127894A1 WO 2022127894 A1 WO2022127894 A1 WO 2022127894A1 CN 2021139052 W CN2021139052 W CN 2021139052W WO 2022127894 A1 WO2022127894 A1 WO 2022127894A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hppd
- amino acid
- plant
- seq
- mutant
- Prior art date
Links
- 239000004009 herbicide Substances 0.000 title claims abstract description 106
- 230000002363 herbicidal effect Effects 0.000 title claims abstract description 79
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 241000196324 Embryophyta Species 0.000 claims description 230
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 197
- 239000012634 fragment Substances 0.000 claims description 94
- 235000007164 Oryza sativa Nutrition 0.000 claims description 82
- 235000009566 rice Nutrition 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 72
- 230000014509 gene expression Effects 0.000 claims description 63
- 238000006467 substitution reaction Methods 0.000 claims description 51
- 150000007523 nucleic acids Chemical class 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 235000010469 Glycine max Nutrition 0.000 claims description 37
- 230000035772 mutation Effects 0.000 claims description 37
- 244000068988 Glycine max Species 0.000 claims description 36
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 239000005578 Mesotrione Substances 0.000 claims description 33
- 238000010362 genome editing Methods 0.000 claims description 31
- KPUREKXXPHOJQT-UHFFFAOYSA-N mesotrione Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)C)=CC=C1C(=O)C1C(=O)CCCC1=O KPUREKXXPHOJQT-UHFFFAOYSA-N 0.000 claims description 30
- 240000008042 Zea mays Species 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 23
- 244000038559 crop plants Species 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 238000012986 modification Methods 0.000 claims description 20
- 108091026890 Coding region Proteins 0.000 claims description 18
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 16
- 235000009973 maize Nutrition 0.000 claims description 16
- 241000209140 Triticum Species 0.000 claims description 15
- 235000021307 Triticum Nutrition 0.000 claims description 15
- 241000209082 Lolium Species 0.000 claims description 14
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 235000007319 Avena orientalis Nutrition 0.000 claims description 12
- 238000002703 mutagenesis Methods 0.000 claims description 11
- 231100000350 mutagenesis Toxicity 0.000 claims description 11
- 241000219194 Arabidopsis Species 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 240000006394 Sorghum bicolor Species 0.000 claims description 9
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 8
- 235000005822 corn Nutrition 0.000 claims description 8
- -1 fenflufen Chemical class 0.000 claims description 8
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 235000007558 Avena sp Nutrition 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- ZTTKDUXKVPEXCG-UHFFFAOYSA-N 2-cyano-3-cyclopropyl-1-(2-mesyl-4-trifluoromethylphenyl)propan-1,3-dione Chemical compound CS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C(C#N)C(=O)C1CC1 ZTTKDUXKVPEXCG-UHFFFAOYSA-N 0.000 claims description 4
- 240000005979 Hordeum vulgare Species 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 150000002545 isoxazoles Chemical class 0.000 claims description 4
- 150000003217 pyrazoles Chemical class 0.000 claims description 4
- AIAYSXFWIUNXRC-PHIMTYICSA-N (1r,5s)-3-[hydroxy-[2-(2-methoxyethoxymethyl)-6-(trifluoromethyl)pyridin-3-yl]methylidene]bicyclo[3.2.1]octane-2,4-dione Chemical compound COCCOCC1=NC(C(F)(F)F)=CC=C1C(O)=C1C(=O)[C@@H](C2)CC[C@@H]2C1=O AIAYSXFWIUNXRC-PHIMTYICSA-N 0.000 claims description 3
- BRQJGZKXHHXWCU-UHFFFAOYSA-N 2-(1-methylcyclopropanecarbonyl)-3-[4-methylsulfonyl-2-(trifluoromethyl)phenyl]-3-oxopropanenitrile Chemical compound C=1C=C(S(C)(=O)=O)C=C(C(F)(F)F)C=1C(=O)C(C#N)C(=O)C1(C)CC1 BRQJGZKXHHXWCU-UHFFFAOYSA-N 0.000 claims description 3
- 239000005571 Isoxaflutole Substances 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 239000005618 Sulcotrione Substances 0.000 claims description 3
- 150000008366 benzophenones Chemical class 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- OYIKARCXOQLFHF-UHFFFAOYSA-N isoxaflutole Chemical compound CS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1=C(C2CC2)ON=C1 OYIKARCXOQLFHF-UHFFFAOYSA-N 0.000 claims description 3
- 229940088649 isoxaflutole Drugs 0.000 claims description 3
- PQTBTIFWAXVEPB-UHFFFAOYSA-N sulcotrione Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)C1C(=O)CCCC1=O PQTBTIFWAXVEPB-UHFFFAOYSA-N 0.000 claims description 3
- WIEXMPDBTYDSQF-UHFFFAOYSA-N 1,3-bis(furan-2-yl)propan-2-one Chemical compound C=1C=COC=1CC(=O)CC1=CC=CO1 WIEXMPDBTYDSQF-UHFFFAOYSA-N 0.000 claims description 2
- 239000012965 benzophenone Substances 0.000 claims description 2
- 241000209763 Avena sativa Species 0.000 claims 2
- 244000061176 Nicotiana tabacum Species 0.000 claims 2
- MTERSQYMYBGZTP-UHFFFAOYSA-N 4-amino-n-(5-methyl-2-phenylpyrazol-3-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 MTERSQYMYBGZTP-UHFFFAOYSA-N 0.000 claims 1
- 229950003013 sulfapyrazole Drugs 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 abstract description 3
- 108010028143 Dioxygenases Proteins 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 134
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 109
- 241000209094 Oryza Species 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 69
- 239000004471 Glycine Substances 0.000 description 61
- 108091033409 CRISPR Proteins 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 35
- 241000208125 Nicotiana Species 0.000 description 32
- 101710163270 Nuclease Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 28
- 108020005004 Guide RNA Proteins 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 238000010354 CRISPR gene editing Methods 0.000 description 20
- 235000004279 alanine Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000009466 transformation Effects 0.000 description 18
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 17
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000004474 valine Substances 0.000 description 12
- 244000075850 Avena orientalis Species 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 238000011529 RT qPCR Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241000209219 Hordeum Species 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 150000002333 glycines Chemical class 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- 235000014304 histidine Nutrition 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108700010070 Codon Usage Proteins 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000009615 deamination Effects 0.000 description 5
- 238000006481 deamination reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- IGMNYECMUMZDDF-UHFFFAOYSA-N homogentisic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O IGMNYECMUMZDDF-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- FKUYMLZIRPABFK-UHFFFAOYSA-N Plastoquinone 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 229920006130 high-performance polyamide Polymers 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- FKUYMLZIRPABFK-IQSNHBBHSA-N plastoquinone-9 Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-IQSNHBBHSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241000589158 Agrobacterium Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102100034782 Homogentisate 1,2-dioxygenase Human genes 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 241000589540 Pseudomonas fluorescens Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- WVXVAFQBNTVPCT-ODZAUARKSA-N (Z)-but-2-enedioic acid 3-oxobutanoic acid Chemical compound C(CC(=O)C)(=O)O.C(\C=C/C(=O)O)(=O)O WVXVAFQBNTVPCT-ODZAUARKSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000219195 Arabidopsis thaliana Species 0.000 description 2
- 241001148727 Bromus tectorum Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 2
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000029812 HNH nuclease Human genes 0.000 description 2
- 108060003760 HNH nuclease Proteins 0.000 description 2
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000030036 Hypertelorism-preauricular sinus-punctual pits-deafness syndrome Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000033016 Lolium rigidum Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 102000048646 human APOBEC3A Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002614 leucines Chemical class 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000003976 plant breeding Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JTBBWRKSUYCPFY-UHFFFAOYSA-N 2,3-dihydro-1h-pyrimidin-4-one Chemical compound O=C1NCNC=C1 JTBBWRKSUYCPFY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- GACSIVHAIFQKTC-UPHRSURJSA-N 4-maleylacetoacetic acid Chemical compound OC(=O)CC(=O)CC(=O)\C=C/C(O)=O GACSIVHAIFQKTC-UPHRSURJSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 description 1
- 241000093740 Acidaminococcus sp. Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 241000588088 Francisella tularensis subsp. novicida U112 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000985215 Homo sapiens 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 101000658622 Homo sapiens Testis-specific Y-encoded-like protein 2 Proteins 0.000 description 1
- 108700023439 Homogentisate 1,2-dioxygenases Proteins 0.000 description 1
- 229940127553 Hydroxyphenylpyruvate Dioxygenase Inhibitors Drugs 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000012245 TALEN-based genome engineering Methods 0.000 description 1
- 102100034917 Testis-specific Y-encoded-like protein 2 Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108700041896 Zea mays Ubi-1 Proteins 0.000 description 1
- 241001148683 Zostera marina Species 0.000 description 1
- 101100339555 Zymoseptoria tritici HPPD gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- VNMCTKGDCLQWGO-UHFFFAOYSA-N pyrazol-3-one 1H-quinazolin-2-one Chemical compound O=C1C=CN=N1.C1=CC=C2NC(=O)N=CC2=C1 VNMCTKGDCLQWGO-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 108091035705 tRNA adenine Proteins 0.000 description 1
- 210000002377 thylakoid Anatomy 0.000 description 1
- 238000003971 tillage Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
Definitions
- the present invention relates to the field of plant genetic engineering.
- the present invention relates to mutants of p-hydroxyphenylpyruvate dioxidase (HPPD) capable of conferring herbicide resistance in plants, and production of mutants comprising said p-hydroxyphenylpyruvate dioxidase (HPPD) Methods of herbicide-resistant plants in vivo.
- HPPD p-hydroxyphenylpyruvate dioxidase
- weed competition A major threat to the production of crops such as rice is weed competition, which can lead to lower grain yields and poor quality.
- tillage can be used to eliminate weeds, the soil of cultivated land is susceptible to erosion by wind and water. Due to ease of application and effectiveness, herbicide treatments are the preferred method of weed control.
- Herbicides can also provide weed control in direct cropping systems that reduce arable land or are designed to leave high levels of residue on the soil surface to prevent erosion.
- herbicide resistance in plants provides important production and economic advantages; therefore, the use of herbicides to control weeds or undesired plants in crops has become almost universal practice. However, the use of such herbicides can also result in the death or reduced growth of the desired crop plants, making the timing and method of herbicide application critical or in some cases not feasible at all.
- One way to address this is to develop herbicide-resistant varieties. In this method, the herbicide is applied to the crop to control weeds without causing damage to the herbicide-resistant crop.
- herbicides with greater potency, broad weed spectrum effectiveness and rapid soil degradation. Plants, plant tissues and seeds that are resistant to these compounds offer an attractive solution by allowing the use of herbicides to control weed growth without the risk of crop damage.
- broad-spectrum herbicides are those compounds that inhibit the activity of p-hydroxyphenylpyruvate dioxidase (HPPD) in plants.
- HPPD p-hydroxyphenylpyruvate dioxidase
- crops such as rice, are susceptible to many HPPD-inhibiting herbicides targeting monocots, making the use of these herbicides to control grass weeds nearly impossible.
- Embodiment 1 An HPPD mutant or functional fragment thereof having an amino acid mutation such as an amino acid substitution at one or more positions selected from positions 365, 378, 414, 415, 417 or 419 relative to wild-type HPPD , the amino acid position is with reference to SEQ ID NO: 1.
- Embodiment 2 The HPPD mutant according to embodiment 1, or a functional fragment thereof, having an amino acid mutation, such as an amino acid substitution, relative to wild-type HPPD, at a position selected from the group consisting of amino acid positions with reference to SEQ ID NO: 1:
- Embodiment 3 The HPPD mutant or functional fragment thereof according to embodiment 1 or 2, said wild-type HPPD comprising the amino acid sequence of one of SEQ ID NOs: 1-13.
- Embodiment 4 The HPPD mutant or functional fragment thereof according to any one of embodiments 1 to 3, which, when expressed in a plant, is capable of conferring resistance to a herbicide to the plant sex.
- Embodiment 5 The HPPD mutant or functional fragment thereof according to Embodiment 4, wherein the herbicide is selected from the group consisting of pyrazole compounds, such as fenflufen, sulfapyr, and fenazopyramide; three Ketones such as sulcotrione, mesotrione, terbotrione, furfuryl ketone, bicyclopyrone, benzobicyclone; isoxazoles such as isoxaflutole; diketonitrile compounds such as 2-cyano-3-cyclopropyl-1-(2-methylsulfonyl-4-trifluoromethylphenyl)-propane-1,3-dione and 2-cyano-1 -[4-(Methylsulfonyl)-2-trifluoromethylphenyl]-3-(1-methylcyclopropyl)propane-1,3-dione; and benzophenone compounds, or them any combination of .
- pyrazole compounds such as
- Embodiment 6 The HPPD mutant or functional fragment thereof according to any one of embodiments 1-5, wherein relative to wild-type HPPD, the HPPD mutant or functional fragment thereof comprises the group selected from L365K, F378A, G414A, One or more amino acid substitutions of said amino acids G414V, G415A, G415V, G417S, G417A, G417K, G419W, G417V, G417R, G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, The position is referenced to SEQ ID NO:1.
- Embodiment 7 The HPPD mutant or functional fragment thereof according to embodiment 6, wherein relative to wild-type HPPD, the HPPD mutant or functional fragment thereof comprises an amino acid substitution selected from the group consisting of
- amino acid positions are referenced to SEQ ID NO: 1.
- Embodiment 8 The HPPD mutant or functional fragment thereof according to any one of embodiments 1-7, said HPPD mutant comprising the amino acid sequence shown in any one of SEQ ID NOs: 14-55.
- Embodiment 9 A nucleic acid comprising a nucleotide sequence encoding the HPPD mutant of any one of embodiments 1-8, or a functional fragment thereof.
- Embodiment 10 An expression cassette comprising a nucleotide sequence encoding the HPPD mutant of any one of embodiments 1-8, or a functional fragment thereof, operably linked to a regulatory sequence.
- Embodiment 11 An expression construct comprising the expression cassette of embodiment 10.
- Embodiment 12 A method of transgenic production of a herbicide-resistant plant comprising introducing the nucleic acid of embodiment 9, the expression cassette of embodiment 10, and/or the expression construct of embodiment 11 into said plant.
- Embodiment 13 A method of producing a herbicide-resistant plant, the method comprising targeted modification of an endogenous HPPD coding sequence of a plant, thereby causing the endogenous HPPD to be selected from the group consisting of: 365, 378, 414, 415, Amino acid mutations at one or more of positions 417 or 419 referenced to SEQ ID NO: 1.
- Embodiment 14 The method according to embodiment 13, wherein the targeted modification results in the endogenous HPPD comprising the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, One or more amino acid substitutions of G417V, G417R, G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:11.
- Embodiment 15 The method according to embodiment 13 or 14, wherein the targeted modification results in the HPPD mutant of any one of embodiments 1-8.
- Embodiment 16 The method according to any one of embodiments 13-15, wherein the coding sequence of the endogenous HPPD is targetedly modified by gene editing or homologous recombination.
- Embodiment 17 The method according to embodiment 16, wherein the gene editing is base editing or prime editing.
- Embodiment 18 A method of producing herbicide-resistant plants, comprising subjecting a population of said plants to physical or chemical mutagenesis, and screening for endogenous HPPD at least selected from the group consisting of 365, 378, 414, 415, 417 Or a plant comprising amino acid mutations at one or more positions, such as 1, 2, 3, 4, 5 or 6 positions at position 419, wherein the amino acid positions are referenced to SEQ ID NO: 1.
- Embodiment 19 The method according to embodiment 18, wherein screening for endogenous HPPD comprises at least selected from L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, G417V, G417R, G417N, Plants with one or more amino acid substitutions of G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:1.
- Embodiment 20 The method according to embodiment 18 or 19, wherein a plant is screened for comprising or expressing the HPPD mutant of any one of embodiments 1-8.
- Embodiment 21 The method according to any one of embodiments 18-20, wherein the physical mutagenesis comprises by irradiation of the plant population and the chemical mutagenesis comprises by treatment with ethyl methanesulfonate (EMS) the plant population.
- EMS ethyl methanesulfonate
- Embodiment 22 The method according to any one of embodiments 12-21, wherein the plant comprises a monocotyledonous or dicotyledonous plant, preferably the plant is a crop plant, such as a monocotyledonous crop plant.
- Embodiment 23 The method according to embodiment 22, wherein the plant is selected from the group consisting of rice, wheat, barley, sorghum, maize, oat, Arabidopsis, ryegrass, brome, wild soybean, soybean, and tobacco.
- Embodiment 24 A herbicide-resistant plant or progeny thereof comprising or expressing the HPPD mutant or functional fragment thereof of any one of embodiments 1-8, or a passage thereof by any of embodiments 12-21 A method is generated.
- Embodiment 25 The herbicide resistant plant or progeny thereof according to embodiment 24, wherein the plant comprises a monocotyledonous or dicotyledonous plant, preferably the plant is a crop plant, eg a monocotyledonous crop plant.
- Embodiment 26 The herbicide-resistant plant or progeny thereof according to embodiment 25, wherein the plant is selected from the group consisting of rice, wheat, barley, sorghum, maize, oat, Arabidopsis, ryegrass, land brome, wild soybean , soy and tobacco.
- Figures 1-6 show mesotrione herbicide resistance mutants tested in in vitro biochemical experiments.
- the herbicide-resistant mutants in the figure are L365K, F378A, G419W, G417A, G417A/F378A, G417S, G417K, G415A, G415V, G414A, G414V, G417V, G417R, G417N, G417D, G417C , G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T.
- the first picture 1 shows that these mutants are all enzymatically active, which means that they can catalyze the substrate (HPPA) to generate products, and have the most basic enzymatic activities for plant growth.
- Figures 2 to 6 show that each mutant has herbicide resistance activity compared with the wild type, the herbicide used is mesotrione, the abscissa is the concentration gradient of mesotrione, and the ordinate is the measured light absorption value calculation The velocity (V) of the resulting product.
- Mutants G417K, G415A, G415V, G414A, G414V are more herbicide resistant than wild type.
- Figure 7 shows double and triple resistance of rice HPPD high resistance loci.
- the Y-axis on the left represents the enzymatic activity, and the Y-axis on the right represents the inhibition constant, and the higher the inhibition constant Ki, the stronger the resistance.
- Figure 8 shows the kinetic constants and inhibition constants (resistance) of the enzymatic reaction of HPPD mutants derived from corn and soybean.
- the corresponding rice-derived HPPD loci are: F378A/G417A, G414A, G417K, G417Q, G417R.
- Figure 9 shows a schematic diagram of the overexpression vector of rice HPPD protein.
- Figure 10 shows the screened phenotypes of rice expressing different resistance mutations when the relative expression levels of HPPD-mRNA are known.
- Figure 11 shows that tobacco expressing the G417K mutation has stronger drug resistance when the relative mRNA expression levels are similar.
- the term “and/or” covers all combinations of the items linked by the term, as if each combination had been individually listed herein.
- “A and/or B” covers “A”, “A and B", and “B”.
- “A, B and/or C” encompasses "A”, “B”, “C”, “A and B”, “A and C”, “B and C”, and "A and B and C”.
- the protein or nucleic acid may consist of the sequence or may have additional amino acids or nuclei at one or both ends of the protein or nucleic acid Glycosides, but still have the activity described in the present invention.
- the methionine encoded by the initiation codon at the N-terminus of the polypeptide is retained in some practical situations (eg, when expressed in a specific expression system), but does not substantially affect the function of the polypeptide.
- Form with respect to a sequence means a sequence from a foreign species, or, if from the same species, a sequence that has been significantly altered in composition and/or locus from its native form by deliberate human intervention.
- nucleic acid sequence is used interchangeably and are polymers of single- or double-stranded RNA or DNA, optionally containing synthetic, non-natural or Altered nucleotide bases.
- Nucleotides are referred to by their single-letter names as follows: “A” for adenosine or deoxyadenosine (for RNA or DNA, respectively), “C” for cytidine or deoxycytidine, “G” for guanosine or Deoxyguanosine, “U” for uridine, “T” for deoxythymidine, “R” for purine (A or G), “Y” for pyrimidine (C or T), “K” for G or T, “ H” means A or C or T, “D” means A, T or G, “I” means inosine, and “N” means any nucleotide.
- Codon optimization refers to replacing at least one codon of a native sequence (eg, about or more than about 1, 2, 3, 4, 5, 10) with a codon that is more or most frequently used in a gene in a host cell. , 15, 20, 25, 50 or more codons while maintaining the native amino acid sequence and modifying the nucleic acid sequence to enhance expression in a host cell of interest.
- Codon bias differences in codon usage between organisms
- mRNA messenger RNA
- tRNA transfer RNA
- the predominance of a selected tRNA within a cell generally reflects the codons most frequently used for peptide synthesis.
- genes can be tailored based on codon optimization for the most efficient use in a given organism Optimal gene expression. Codon utilization tables are readily available, for example in the codon usage database ("Codon Usage Database") available at www.kazusa.orjp/codon/, and these tables can be adjusted in different ways Applicable. See, Nakamura Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28:292 (2000).
- Polypeptide “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
- the term applies to amino acid polymers in which one or more amino acid residues is an artificial chemical analog of the corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
- the terms "polypeptide”, “peptide”, “amino acid sequence” and “protein” may also include modified forms including, but not limited to, glycosylation, lipid linkage, sulfation, gamma carboxylation of glutamic acid residues, hydroxyl sylation and ADP-ribosylation.
- Sequence "identity” has an art-recognized meaning, and the percent sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along regions of the molecule.
- identity is well known to the skilled artisan (Carrillo, H. & Lipman, D., SIAM J Applied Math 48:1073 (1988) ).
- Suitable conservative amino acid substitutions are known to those of skill in the art and can generally be made without altering the biological activity of the resulting molecule.
- those skilled in the art recognize that single amino acid substitutions in non-essential regions of polypeptides do not substantially alter biological activity (see, e.g., Watson et al., Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub .co., p.224).
- expression construct refers to a vector such as a recombinant vector suitable for expression of a nucleotide sequence of interest in an organism.
- “Expression” refers to the production of a functional product.
- expression of a nucleotide sequence can refer to transcription of the nucleotide sequence (eg, transcription to produce mRNA or functional RNA) and/or translation of RNA into a precursor or mature protein.
- the "expression construct" of the present invention may be a linear nucleic acid fragment, circular plasmid, viral vector, or, in some embodiments, may be an RNA (eg, mRNA) capable of translation, eg, RNA produced by in vitro transcription.
- RNA eg, mRNA
- An "expression construct" of the present invention may comprise regulatory sequences and nucleotide sequences of interest from different sources, or regulatory sequences and nucleotide sequences of interest from the same source but arranged in a manner different from that normally found in nature.
- regulatory sequence and “regulatory element” are used interchangeably and refer to a coding sequence upstream (5' non-coding sequence), intermediate or downstream (3' non-coding sequence) and affecting transcription, RNA processing or Stability or translated nucleotide sequence. Regulatory sequences can include, but are not limited to, promoters, translation leader sequences, introns, and polyadenylation recognition sequences.
- Promoter refers to a nucleic acid segment capable of controlling the transcription of another nucleic acid segment.
- a promoter is a promoter capable of controlling the transcription of a gene in a cell, whether or not it is derived from the cell.
- the promoter may be a constitutive promoter or a tissue-specific promoter or a developmentally regulated promoter or an inducible promoter.
- tissue-specific promoter and “tissue-preferred promoter” are used interchangeably and refer to expression primarily, but not necessarily exclusively, in a tissue or organ, but also in a particular cell or cell type promoter.
- tissue-preferred promoter refers to a promoter whose activity is determined by developmental events.
- inducible promoter selectively expresses an operably linked DNA sequence in response to endogenous or exogenous stimuli (environmental, hormonal, chemical signals, etc.).
- promoters include, but are not limited to, polymerase (pol) I, pol II, or pol III promoters.
- the promoter may be the cauliflower mosaic virus 35S promoter, the maize Ubi-1 promoter, the wheat U6 promoter, the rice U3 promoter, the maize U3 promoter, the rice actin promoter.
- operably linked refers to regulatory elements (eg, but not limited to, promoter sequences, transcription termination sequences, etc.) are linked to a nucleic acid sequence (eg, a coding sequence or open reading frame) such that nucleotides Transcription of the sequence is controlled and regulated by the transcriptional regulatory elements.
- a nucleic acid sequence eg, a coding sequence or open reading frame
- "Introducing" a nucleic acid molecule (eg, plasmid, linear nucleic acid fragment, RNA, etc.) or protein into an organism refers to transforming the cells of the organism with the nucleic acid or protein so that the nucleic acid or protein can function in the cell.
- "Transformation” as used in the present invention includes stable transformation and transient transformation.
- “Stable transformation” refers to the introduction of a foreign nucleotide sequence into the genome, resulting in the stable inheritance of the foreign gene. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof.
- Transient transformation refers to the introduction of a nucleic acid molecule or protein into a cell to perform a function without the stable inheritance of an exogenous gene. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.
- plant includes whole plants and any progeny, cells, tissues, or parts of plants.
- plant part includes any part of a plant, including, for example, but not limited to: seeds (including mature seeds, immature embryos without seed coats, and immature seeds); plant cuttings; plant cells; Plant cell cultures; plant organs (eg, pollen, embryos, flowers, fruits, shoots, leaves, roots, stems, and related explants).
- a plant tissue or plant organ can be a seed, callus, or any other population of plant cells organized into structural or functional units.
- a plant cell or tissue culture is capable of regenerating plants having the physiological and morphological characteristics of the plant from which the cell or tissue is derived, and capable of regenerating plants having substantially the same genotype as the plant. In contrast, some plant cells are unable to regenerate to produce plants.
- the regenerable cells in plant cells or tissue culture can be embryos, protoplasts, meristems, callus, pollen, leaves, anthers, roots, root tips, silks, flowers, nuts, ears, cobs, shells , or stem.
- Plant “progeny” includes any subsequent generation of the plant.
- HPPD P-hydroxyphenylpyruvate dioxidase
- p-Hydroxyphenylpyruvate is converted to homogentisate under the catalysis of HPPD enzyme.
- Urogentine is further decarboxylated and alkylated to generate plastoquinone and tocopherol.
- Plastoquinone acts as the final electron acceptor and electron transporter in the photosynthetic chain in carotenoid biosynthesis, and the lack of plastoquinone in thylakoid will lead to reduced carotenoid biosynthesis.
- HPPD p-Hydroxyphenylpyruvate dioxidase
- HPPD-inhibiting herbicides include, but are not limited to, pyrazoles, triketones, isoxazoles, diketonitriles, and benzophenones, or any combination thereof.
- Suitable pyrazole compounds include, but are not limited to, fenflufenazone (Baowei), sulfofenapyr, acid fenazopyramide, and the like.
- Suitable triketone compounds include, but are not limited to, sulcotrione, mesotrione, terbotrione, tefurfuryl ketone, bicyclopyrone, benzobicyclone, and the like.
- Suitable isoxazoles include, but are not limited to, isoxaflutole.
- Suitable diketonitriles include, but are not limited to, 2-cyano-3-cyclopropyl-1-(2-methylsulfonyl-4-trifluoromethylphenyl)-propane-1,3-dione and 2-cyano-1-[4-(methylsulfonyl)-2-trifluoromethylphenyl]-3-(1-methylcyclopropyl)propane-1,3-dione.
- the inventors created and identified novel HPPD mutants resistant to HPPD-inhibiting herbicides by prokaryotic expression and enzyme activity analysis techniques.
- the present invention provides a p-hydroxyphenylpyruvate dioxidase (HPPD) mutant or a functional fragment thereof, which is at least selected from the group consisting of 365, 378, 414, 415 relative to the wild-type HPPD.
- HPPD p-hydroxyphenylpyruvate dioxidase
- the HPPD mutant or functional fragment thereof, relative to wild-type HPPD has at least 1, 2, 3, There were amino acid mutations at positions 5 or 6, referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has amino acid mutations at least at positions 378 and 415 relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant, or a functional fragment thereof, has amino acid mutations at least at positions 378 and 417 relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant, or a functional fragment thereof, has amino acid mutations at least at positions 414 and 417 relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof has amino acid mutations at least at positions 378, 415 and 417 relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1.
- an amino acid position with reference to SEQ ID NO:x refers to the position number of the specific amino acid being described that is the amino acid in SEQ ID NO:x The position number of the corresponding amino acid above.
- sequence alignment methods well known in the art. For example amino acid correspondences can be determined by the online alignment tool of EMBL-EBI (https://www.ebi.ac.uk/Tools/psa/), where two sequences can be determined using the Needleman-Wunsch algorithm using default parameters to Align.
- the alanine at position 360 of a polypeptide from its N-terminus is aligned with the amino acid at position 365 of SEQ ID NO:x in a sequence alignment, then the alanine in the polypeptide may also be used herein. Described as "Alanine at position 365 of the polypeptide, the amino acid position referenced to SEQ ID NO:x".
- the glycine at position 412 in the real position of the amino acid sequence SEQ ID NO: 9 of the present invention is aligned with the glycine at position 417 in SEQ ID NO: 1 in the sequence alignment, then the glycine in SEQ ID NO: 9 is aligned.
- the glycine may also be described herein as "the glycine at position 417 of SEQ ID NO:9, the amino acid position referenced to SEQ ID NO:1".
- the HPPD mutant or functional fragment thereof when expressed in a plant, is capable of conferring resistance to a herbicide, eg, an HPPD-inhibiting herbicide, to the plant.
- a herbicide eg, an HPPD-inhibiting herbicide
- Conferring resistance to a herbicide, such as an HPPD-inhibiting herbicide, to the plant refers to the resistance of a plant comprising or expressing the HPPD mutant or functional fragment thereof to a herbicide, such as an HPPD-inhibiting herbicide, relative to Plants that do not contain or express the HPPD mutant or a functional fragment thereof or only contain or express (a comparable amount) wild-type HPPD are enhanced, e.g. by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or higher.
- the herbicide-resistant plants of the present invention are capable of at least 1 ⁇ mol/L, at least 1.5 ⁇ mol/L, at least 1.8 ⁇ mol/L, at least 2 ⁇ mol/L, at least 3 ⁇ mol/L, at least 5 ⁇ mol/L, at least 10 mol Normal growth was exhibited in the presence of herbicides (eg, HPPD-inhibiting herbicides such as mesotrione) at concentrations of /L or higher.
- herbicides eg, HPPD-inhibiting herbicides such as mesotrione
- Resistance of HPPD mutants or functional fragments thereof of the present invention to HPPD-inhibiting herbicides can be determined in vitro by the enzymatic reaction kinetics method described herein, eg, see the method described in Example 4.
- the resistance of HPPD mutants or functional fragments thereof of the present invention to HPPD-inhibiting herbicides can be determined in vivo by detecting the growth status of plants comprising said mutants or functional fragments thereof in the presence of HPPD-inhibiting herbicides, See, for example, the method described in Example 5.
- the wild-type HPPD comprises the amino acid sequence of one of SEQ ID NOs: 1-13.
- the amino acid sequence of the wild-type HPPD is, for example, one of SEQ ID NOs: 1-13.
- the wild-type HPPD is, for example, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% of the amino acid sequence of one of SEQ ID NOs: 1-13 , a naturally occurring variant of one of SEQ ID NOs: 1-13 having at least 98%, at least 99%, at least 99.5%, at least 99.9% sequence identity.
- the HPPD mutant is derived from rice wild-type HPPD.
- An exemplary rice wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:1.
- the HPPD mutant is derived from a wheat (Triticum aestivum) wild-type HPPD.
- Exemplary wheat wild-type HPPDs comprise the amino acid sequences set forth in SEQ ID NO: 2, 3 or 4.
- the HPPD mutant is derived from Avena sativa wild-type HPPD.
- An exemplary oat wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:5.
- the HPPD mutant is derived from Pseudomonas fluorescens wild-type HPPD.
- An exemplary Pseudomonas fluorescens wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:6.
- the HPPD mutant is derived from Lolium rigidum wild-type HPPD.
- An exemplary ryegrass wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:7.
- the HPPD mutant is derived from Bromus tectorum wild-type HPPD.
- An exemplary land brome wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:8.
- the HPPD mutant is derived from Zea mays wild-type HPPD.
- An exemplary corn wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:9.
- the HPPD mutant is derived from a barley (Hordeum vulgare) wild-type HPPD.
- An exemplary barley wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:10.
- the HPPD mutant is derived from Glycine soja wild-type HPPD.
- An exemplary wild soybean wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:11.
- the HPPD mutant is derived from Arabidopsis thaliana wild-type HPPD.
- An exemplary Arabidopsis wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:12.
- the HPPD mutant is derived from soybean (Glycine max) wild-type HPPD.
- An exemplary soybean wild-type HPPD comprises the amino acid sequence set forth in SEQ ID NO:13.
- the amino acid mutation is an amino acid substitution.
- the HPPD mutant or functional fragment thereof is substituted at the leucine (L) at position 365 relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof is substituted at phenylalanine (F) at position 378 relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof has a glycine (G) substitution at position 414, relative to wild-type HPPD, referenced to SEQ ID NO: 1 for the amino acid position.
- the HPPD mutant or functional fragment thereof has a glycine (G) substitution at position 415, relative to wild-type HPPD, referenced to SEQ ID NO: 1 for the amino acid position.
- the HPPD mutant or functional fragment thereof has a glycine (G) substitution at position 417 relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof is substituted at glycine (G) at position 419, relative to wild-type HPPD, at the amino acid position referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof is substituted at phenylalanine (F) at position 378 and glycine (G) at position 417 relative to wild-type HPPD, the amino acid positions See SEQ ID NO:1. In some embodiments, the HPPD mutant or functional fragment thereof is substituted at phenylalanine (F) at position 378 and glycine (G) at position 415 relative to wild-type HPPD, the amino acid positions See SEQ ID NO:1. In some embodiments, the HPPD mutant or functional fragment thereof is substituted at glycine (G) at position 414 and glycine (G) at position 417 relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a phenylalanine (F) at position 378, a glycine (G) at position 415, and a glycine at position 417 relative to wild-type HPPD (G) is substituted, and the amino acid positions are referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a leucine (L) at position 365 replaced by a lysine (K) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO :1.
- the HPPD mutant or functional fragment thereof is substituted with alanine (A) at position 378 of phenylalanine (F) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof is substituted with an alanine (A) at position 414 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 3 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 414 replaced by a valine (V) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 415 replaced by an alanine (A) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 415 replaced by a valine (V) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a serine (S) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by an alanine (A) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a lysine (K) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with tryptophan (W) at glycine (G) at position 419, relative to wild-type HPPD, at the amino acid position referenced in SEQ ID NO: 1.
- W tryptophan
- G glycine
- the HPPD mutant or functional fragment thereof is replaced by an alanine (A) at a phenylalanine (F) at position 378 and a glycine (G) at position 417, respectively, relative to wild-type HPPD ) substitution, the amino acid positions are referred to SEQ ID NO: 13.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a valine (V) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with an arginine (R) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with an asparagine (N) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with an aspartic acid (D) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a cysteine (C) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof is substituted with glutamine (Q) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a glutamic acid (E) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with a histidine (H) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with isoleucine (I) at position 417 of glycine (G) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced with a methionine (M) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a phenylalanine (F) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1.
- the HPPD mutant or functional fragment thereof has a glycine (G) at position 417 replaced by a proline (P) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof is substituted with a glycine (G) at position 417 by a threonine (T) relative to wild-type HPPD, the amino acid position being referenced to SEQ ID NO: 1 .
- the HPPD mutant or functional fragment thereof comprises at least one selected from the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, One or more amino acid substitutions of G417V, G417R, G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:1.
- the HPPD mutant or functional fragment thereof comprises at least one selected from the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, One amino acid substitution of G417V, G417R, G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:1.
- the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G415A relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G415V relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G417K relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO:1.
- the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G417R relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G417V relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO: 1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A and G417A relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO:1.
- the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions G414V and G417K relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO:1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A, G415A and G417A relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO:1. In some embodiments, the HPPD mutant or functional fragment thereof comprises at least the amino acid substitutions F378A, G415V and G417K relative to wild-type HPPD, the amino acid positions being referenced to SEQ ID NO:1.
- “functional fragment” refers to a fragment that retains at least partially or fully the function of the full-length HPPD mutant from which it is derived.
- the HPPD mutant or functional fragment thereof further comprises one or more additional amino acid mutations, eg, conservative amino acid substitutions, relative to wild-type HPPD.
- additional amino acid mutations eg, conservative amino acid substitutions
- those skilled in the art will appreciate that small amino acid insertions, deletions or additions at the termini (C-terminus and/or N-terminus) of a protein generally do not significantly alter the function of the protein.
- a tag such as a histidine tag, can be added to the end of the protein to facilitate protein purification and/or detection.
- the HPPD mutant comprises at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% of any of SEQ ID NOs: 14-55 %, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% amino acid sequences of sequence identity.
- the HPPD mutant comprises the amino acid sequence set forth in any of SEQ ID NOs: 14-55.
- the present invention also provides a nucleic acid comprising a nucleotide sequence encoding the HPPD mutant of the present invention or a functional fragment thereof.
- the nucleic acid is an isolated nucleic acid or a recombinant nucleic acid.
- nucleotide sequences encoding the HPPD mutants of the invention or functional fragments thereof may be codon-optimized for the plant of interest.
- the present invention also provides an expression cassette comprising a nucleotide sequence encoding an HPPD mutant or a functional fragment thereof operably linked to a regulatory sequence.
- the present invention also provides an expression construct comprising the expression cassette of the present invention.
- the present invention also provides the use of an HPPD mutant of the present invention or a functional fragment thereof, an isolated nucleic acid of the present invention, an expression cassette of the present invention, or an expression construct of the present invention in the production of herbicide-resistant plants .
- the present invention also provides a herbicide-resistant plant comprising or expressing the HPPD mutant of the present invention or a functional fragment thereof.
- the plants described in various aspects of the invention may be plants susceptible to HPPD inhibitors, including monocotyledonous or dicotyledonous plants.
- the plant is a crop plant, such as a monocotyledonous crop plant.
- suitable plants include, but are not limited to, rice, wheat, barley, sorghum, maize, oats, Arabidopsis, ryegrass, brome, wild soybean, soybean, or tobacco, and the like.
- the plant is rice.
- the plant is maize.
- the plant is soybean.
- the plant is tobacco.
- the present invention also provides a method of transgenic production of herbicide-resistant plants, comprising introducing a nucleic acid of the present invention, an expression cassette of the present invention and/or an expression construct of the present invention into a plant.
- introduction of the nucleic acid of the invention, the expression cassette of the invention and/or the expression construct of the invention results in the plant comprising or expressing the HPPD mutant of the invention or a functional fragment thereof.
- nucleic acid of the invention, the expression cassette of the invention and/or the expression construct of the invention can be introduced into the plant using various methods known in the art. Suitable methods of introduction include, but are not limited to, biolistic, PEG-mediated protoplast transformation, Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube passage, and ovary injection.
- nucleic acid of the invention, the expression cassette of the invention and/or the expression construct of the invention are integrated into the genome of the plant.
- isolated nucleic acids of the invention, the expression cassettes of the invention and/or the expression constructs of the invention will confer resistance to said plants to herbicides capable of inhibiting HPPD activity.
- the present invention also provides a herbicide-resistant plant comprising, or consisting of, an expression cassette of the present invention, a nucleic acid or an expression construct of the present invention, or a nucleic acid of the present invention, an expression cassette of the present invention and/or The expression constructs of the present invention are transformed.
- the present invention also encompasses the progeny of said herbicide-resistant plants.
- the plants described in various aspects of the invention may be plants susceptible to HPPD inhibitors, including monocotyledonous or dicotyledonous plants.
- the plant is a crop plant, such as a monocotyledonous crop plant.
- suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, oats, Arabidopsis, ryegrass, ryegrass, wild soybean, soybean, and tobacco, among others.
- the plant is rice.
- the plant is maize.
- the plant is soybean.
- the plant is tobacco.
- the plant endogenous HPPD can be engineered through targeted mutation, thereby generating herbicide-resistant plants.
- the present invention also provides a method of producing a herbicide-resistant plant, the method comprising modifying, eg, targeted modification of an endogenous HPPD coding sequence of the plant, thereby resulting in the endogenous HPPD (eg, an expressed endogenous HPPD) amino acid mutation at one or more positions selected from the group consisting of positions 365, 378, 414, 415, 417 or 419, for example at positions 1, 2, 3, 4, 5 or 6, the amino acid The position is referenced to SEQ ID NO:1.
- the plant's endogenous HPPD for example, comprises the amino acid sequence of one of SEQ ID NOs: 1-13 or is at least 80%, at least 85%, at least 90%, at least 80%, at least 85%, at least 90% identical to the amino acid sequence of one of SEQ ID NO: 1-13.
- the modification results in the substitution of a leucine (L) at position 365 and/or a phenylalanine at position 378 ( F) is substituted, and/or glycine (G) at position 414 is substituted, and/or glycine (G) at position 415 is substituted, and/or glycine (G) at position 417 is substituted, and/or Glycine (G) at position 419 is substituted, the amino acid position is referenced to SEQ ID NO: 1.
- the modification results in the replacement of a leucine (L) with a lysine (K) at position 365 of the endogenous HPPD (eg, expressed endogenous HPPD), and/or at position 378
- the phenylalanine (F) is replaced by alanine (A)
- the glycine (G) at position 414 is replaced by alanine (A) or valine (V)
- Glycine (G) at position 415 is replaced by alanine (A) or valine (V)
- glycine (G) at position 417 is replaced by serine (S) or alanine (A) or lysine acid (K) or valine (V) or arginine (R) or asparagine (N) or aspartic acid (D) or cysteine (C) or glutamine (Q) or glutamine Amino acid (E) or histidine (H) or isoleucine (I) or methion
- the modification results in that the endogenous HPPD (eg, expressed endogenous HPPD) comprises a group selected from the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, One or more amino acid substitutions of G417V, G417R, G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:1.
- the endogenous HPPD comprises a group selected from the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417
- the modification results in the HPPD mutant of the invention described above, eg, causes the plant to express the HPPD mutant of the invention described above.
- the present invention also provides a method of producing a herbicide-resistant plant, the method comprising modifying, for example, the targeted modification of an endogenous HPPD coding sequence of the plant, thereby resulting in the HPPD mutant of the invention hereinabove, for example, resulting in the The plants express the HPPD mutants of the present invention described above.
- a "herbicide-resistant plant” may refer to a plant in which the endogenous HPPD coding sequence of the invention has been targetedly modified, relative to a plant without said targeted modification, having increased resistance to HPPD-inhibiting herbicides, eg, enhanced 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or higher.
- Methods for determining resistance to HPPD-inhibiting herbicides are known in the art. Resistance can be readily determined by one skilled in the art for a specific plant and specific herbicide.
- the herbicide-resistant plants of the present invention are capable of at least 1 ⁇ mol/L, at least 1.5 ⁇ mol/L, at least 1.8 ⁇ mol/L, at least 2 ⁇ mol/L, at least 3 ⁇ mol/L, at least 5 ⁇ mol/L, at least 10 mol Normal growth was exhibited in the presence of herbicides (eg, HPPD-inhibiting herbicides such as mesotrione) at concentrations of /L or higher.
- herbicides eg, HPPD-inhibiting herbicides such as mesotrione
- the endogenous HPPD coding sequence of the plant is targeted for modification by homologous recombination.
- Methods of modifying endogenous genes in plants by homologous recombination are well known to those skilled in the art.
- the endogenous HPPD coding sequence of the plant is targeted for modification by gene editing. In some embodiments, the plant's endogenous HPPD coding sequence is targeted for modification by introducing into the plant a gene editing system that targets the endogenous HPPD coding region in the plant genome.
- introduction of the gene editing system results in an amino acid mutation of the endogenous HPPD at one or more positions selected from positions 365, 378, 414, 415, 417, or 419, the amino acid positions See SEQ ID NO:1.
- introduction of the gene editing system results in the substitution of the endogenous HPPD for a leucine (L) at position 365, and/or a substitution for a phenylalanine (F) at position 378 , and/or substituted glycine (G) at position 414, and/or substituted glycine (G) at position 415, and/or substituted glycine (G) at position 417, and/or substituted at position 417 Glycine (G) at position 419 is substituted, and the amino acid position is referenced to SEQ ID NO: 1.
- introduction of the gene editing system results in the substitution of leucine (L) with lysine (K) at position 365 of the endogenous HPPD, and/or phenylalanine at position 378
- Acid (F) is replaced by alanine (A)
- glycine (G) at position 414 is replaced by alanine (A) or valine (V)
- glycine at position 415 (G) is replaced by alanine (A) or valine (V)
- glycine (G) at position 417 is replaced by serine (S) or alanine (A) or lysine (K) or valine (V) or arginine (R) or asparagine (N) or aspartic acid (D) or cysteine (C) or glutamine (Q) or glutamic acid (E ) or histidine (H) or isoleucine (I) or methionine (M) or phenylalanine (F) or pro
- introduction of the gene editing system results in the endogenous HPPD comprising L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, G417V, G417R, One or more amino acid substitutions of G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions referenced to SEQ ID NO:1.
- introduction of the gene editing system results in the HPPD mutant of the invention above, eg, causes the plant to express the HPPD mutant of the invention above.
- the gene editing system usable in the present invention may be various gene editing systems known in the art as long as it enables targeted genome editing in plants.
- the gene editing system may be a CRISPR, ZFN or TALEN based gene editing system.
- the gene editing system is a CRISPR-based gene editing system.
- the gene editing system is a base editing system.
- the base editing system usable in the present invention may be various base editing systems known in the art as long as it can perform targeted genome base editing in plants.
- base editing systems include, but are not limited to, those described in WO 2018/056623, WO 2019/120283, WO 2019/120310.
- the base editing system comprises a base editing fusion protein or an expression construct comprising a nucleotide sequence encoding the same, and at least one guide RNA or an expression construct comprising a nucleotide sequence encoding the same body, such as the system comprising at least one of the following i) to v):
- RNA a base editing fusion protein, and at least one guide RNA
- an expression construct comprising a nucleotide sequence encoding a base-edited fusion protein, and at least one guide RNA;
- an expression construct comprising a nucleotide sequence encoding a base-edited fusion protein, and an expression construct comprising a nucleotide sequence encoding at least one guide RNA;
- the base editing fusion protein comprises a CRISPR effector protein and a deaminase domain
- the at least one guide RNA is capable of targeting the base editing fusion protein to an endogenous HPPD coding sequence in the plant genome.
- base editing fusion protein and “base editor” are used interchangeably and refer to a protein that can mediate one or more nucleotide substitutions of a target sequence in a genome in a sequence-specific manner protein.
- CRISPR effector protein generally refers to nucleases (CRISPR nucleases) or functional variants thereof that occur in naturally occurring CRISPR systems.
- the term encompasses any effector protein based on the CRISPR system capable of sequence-specific targeting within a cell.
- a "functional variant" with respect to a CRISPR nuclease means that it retains at least the guide RNA-mediated sequence-specific targeting ability.
- the functional variant is a nuclease inactive variant, ie it lacks double-stranded nucleic acid cleavage activity.
- CRISPR nucleases lacking double-stranded nucleic acid cleavage activity also encompass nickases that form a nick in a double-stranded nucleic acid molecule, but do not completely cleave the double-stranded nucleic acid.
- the CRISPR effector protein of the present invention has nickase activity.
- the functional variant recognizes a different PAM (Prospacer Adjacent Motif) sequence relative to the wild-type nuclease.
- Cas9 nucleases can be derived from Cas9 nucleases, including Cas9 nucleases or functional variants thereof.
- the Cas9 nuclease may be a Cas9 nuclease from a different species, eg spCas9 from S. pyogenes or SaCas9 from S. aureus.
- Cas9 nuclease and Cas9 are used interchangeably herein to refer to an RNA comprising a Cas9 protein or fragment thereof (eg, a protein comprising the active DNA cleavage domain of Cas9 and/or the gRNA binding domain of Cas9) directed nucleases.
- Cas9 is a component of the CRISPR/Cas (clustered regularly interspaced short palindromic repeats and related systems) genome editing system, which can target and cleave DNA target sequences under the guidance of guide RNA to form DNA double-strand breaks (DSBs). ).
- CRISPR/Cas clustered regularly interspaced short palindromic repeats and related systems
- CRISPR effector proteins can also be derived from Cpf1 nucleases, including Cpf1 nucleases or functional variants thereof.
- the Cpf1 nuclease may be a Cpf1 nuclease from a different species, such as Cpf1 nucleases from Francisella novicida U112, Acidaminococcus sp. BV3L6 and Lachnospiraceae bacterium ND2006.
- CRISPR effector proteins can also be derived from Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, GSU0054, Cas10, Csm2, Cmr5, Cas10, Csx11, Csx10, Csf1, Csn2 , Cas4, C2c1, C2c3 or C2c2 nucleases, for example including these nucleases or functional variants thereof.
- the CRISPR effector protein is nuclease-inactive Cas9.
- the DNA cleavage domain of the Cas9 nuclease is known to contain two subdomains: the HNH nuclease subdomain and the RuvC subdomain.
- the HNH subdomain cleaves the strand complementary to the gRNA, while the RuvC subdomain cleaves the non-complementary strand. Mutations in these subdomains can inactivate the nuclease activity of Cas9, forming "nuclease-inactive Cas9".
- the nuclease-inactivated Cas9 still retains the DNA binding ability directed by the gRNA.
- the nuclease-inactive Cas9 of the present invention can be derived from different species of Cas9, for example, from S. pyogenes Cas9 (SpCas9), or from S. aureus Cas9 (SaCas9) ). Simultaneous mutation of the HNH nuclease subdomain and RuvC subdomain of Cas9 (eg, comprising mutations D10A and H840A) inactivates the nuclease of Cas9, becoming nuclease-dead Cas9 (dCas9).
- SpCas9 S. pyogenes Cas9
- SaCas9 S. aureus Cas9
- nCas9 Cas9 nickase
- D10A D10A
- Cas9 nuclease When Cas9 nuclease is used for gene editing, it is usually required that the target sequence has a PAM (prespacer adjacent motif) sequence of 5'-NGG-3' at the 3' end.
- PAM prespacer adjacent motif
- this PAM sequence appears infrequently in some species such as rice, greatly limiting gene editing in these species such as rice.
- CRISPR effector proteins that recognize different PAM sequences such as Cas9 nuclease functional variants with different PAM sequences, are preferably used in the present invention.
- the CRISPR effector protein is a Cas9 variant that recognizes the PAM sequence 5'-NG-3'. In some preferred embodiments, the CRISPR effector protein is a nuclease-inactive Cas9 variant that recognizes the PAM sequence 5'-NG-3'.
- deaminase domains described herein can be cytosine deamination domains or adenine deamination domains.
- cytosine deamination domain refers to a domain capable of accepting single-stranded DNA as a substrate to catalyze the deamination of cytidine or deoxycytidine to uracil or deoxyuracil, respectively.
- cytosine deaminase useful in the present invention include, but are not limited to, eg, APOBEC1 deaminase, activation-induced cytidine deaminase (AID), APOBEC3G, CDA1, human APOBEC3A deaminase, or functional variants thereof. body.
- the cytosine deaminase is human APOBEC3A deaminase or a functional variant thereof.
- adenine deamination domain refers to a domain capable of accepting single-stranded DNA as a substrate and catalyzing the formation of inosine (I) from adenosine or deoxyadenosine (A).
- the adenine deaminase is a variant of the E. coli tRNA adenine deaminase TadA (ecTadA).
- guide RNA and “gRNA” are used interchangeably and refer to an RNA capable of forming a complex with a CRISPR effector protein and capable of targeting the complex to a target sequence due to some identity to the target sequence molecular.
- the guide RNA targets the target sequence by base pairing with the complementary strand of the target sequence.
- a gRNA employed by a Cas9 nuclease or a functional variant thereof typically consists of partially complementary crRNA and tracrRNA molecules forming a complex, wherein the crRNA comprises sufficient identity to the target sequence to hybridize to the complementary strand of the target sequence and direct
- the CRISPR complex (Cas9+crRNA+tracrRNA) is a guide sequence (also called a seed sequence) that specifically binds to the target sequence.
- sgRNAs single guide RNAs
- gRNAs employed by Cpf1 nucleases or functional variants thereof usually consist of only mature crRNA molecules, which may also be referred to as sgRNAs. It is within the skill of the artisan to design a suitable gRNA based on the CRISPR nuclease used and the target sequence to be edited.
- the at least one gRNA of the present invention comprises a target sequence in the coding region of the endogenous HPPD, and the amino acid sequence encoded by the target sequence comprises the endogenous HPPD selected from the group consisting of 365, 378, An amino acid at one or more of positions 414, 415, 417, or 419, such as at positions 1, 2, 3, 4, 5, or 6, with reference to SEQ ID NO: 1.
- the gene editing system is a so-called prime editing system.
- the system includes a fusion of a Cas nuclease with target strand nicking activity (eg, Cas9-H840A) and a reverse transcriptase (eg, M-MLV reverse transcriptase), and a 3' end with a repair template (RT template) and Free single-stranded binding region (PBS) pegRNA (prime editing gRNA, guide editing gRNA).
- RT template repair template
- PBS Free single-stranded binding region
- the system uses PBS to bind the free single strands generated by Cas nickase (such as Cas9-H840A), and make it transcribe single-stranded DNA sequences according to a given RT template.
- the PAM sequence can be located in the genome. - Any change in DNA sequence downstream of position 3.
- Anzalone A. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature https://doi.org/10.1038/s41586-019-1711 -4 (2019).
- the gene editing system can be introduced into plants by various methods well known to those skilled in the art. Methods that can be used to introduce the gene editing system of the present invention into plants include, but are not limited to: biolistic, PEG-mediated protoplast transformation, Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube pathway, and ovary injection.
- the modification of the target sequence can be achieved only by introducing or producing the gene editing system in a plant cell, and the modification can be stably inherited without the need to stably transform the gene editing system into a plant. This avoids potential off-target effects of stably existing gene editing systems, and also avoids the integration of exogenous nucleotide sequences into the plant genome, resulting in higher biological safety.
- the introduction is performed in the absence of selective pressure, thereby avoiding integration of foreign nucleotide sequences into the plant genome.
- the introducing comprises transforming the gene editing system of the invention into an isolated plant cell or tissue, and then regenerating the transformed plant cell or tissue into a whole plant.
- the regeneration is carried out in the absence of selective pressure, that is, without the use of any selection agent for the selection gene carried on the expression vector during tissue culture. Without the use of a selection agent, the regeneration efficiency of plants can be improved, and herbicide-resistant plants without exogenous nucleotide sequences can be obtained.
- the gene editing systems of the present invention can be transformed into specific sites on intact plants, such as leaves, shoot tips, pollen tubes, young ears, or hypocotyls. This is particularly suitable for the transformation of plants that are difficult to regenerate in tissue culture.
- the in vitro expressed protein and/or in vitro transcribed RNA molecule is directly transformed into the plant.
- the protein and/or RNA molecules enable gene editing in plant cells and are subsequently degraded by the cells, avoiding the integration of exogenous nucleotide sequences into the plant genome.
- the present invention also provides a herbicide-resistant plant produced by the method of the present invention for targeted modification of endogenous HPPD in a plant.
- the present invention also encompasses the progeny of said herbicide-resistant plants.
- the herbicide-resistant plant is non-transgenic.
- the plants described in various aspects of the invention may be plants susceptible to HPPD inhibitors, including monocotyledonous or dicotyledonous plants.
- the plant is a crop plant, such as a monocotyledonous crop plant.
- suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, oats, Arabidopsis, ryegrass, ryegrass, wild soybean, soybean, and tobacco, and the like.
- the plant is rice.
- the plant is maize.
- the plant is soybean.
- the plant is tobacco.
- the present invention also provides a method of producing herbicide-resistant plants comprising physically or chemically mutagenizing a population of said plants and screening for endogenous HPPD (eg, expressed endogenous HPPD) for at least A plant comprising an amino acid mutation at one or more positions selected from the group consisting of positions 365, 378, 414, 415, 417 or 419, eg, 1, 2, 3, 4, 5 or 6 positions, wherein said amino acid positions refer to SEQ ID NO: 1.
- endogenous HPPD eg, expressed endogenous HPPD
- the screening endogenous HPPD (eg, expressed endogenous HPPD) has at least a leucine (L) substitution at position 365, and/or a phenylalanine (F) substitution at position 378 , and/or substituted glycine (G) at position 414, and/or substituted glycine (G) at position 415, and/or substituted glycine (G) at position 417, and/or substituted at position 417
- L leucine
- F phenylalanine
- the endogenous HPPD (eg, expressed endogenous HPPD) is screened for at least substitution of leucine (L) with lysine (K) at position 365, and/or phenylalanine at position 378 Acid (F) is replaced by alanine (A), and/or glycine (G) at position 414 is replaced by alanine (A) or valine (V), and/or glycine at position 415 (G) is replaced by alanine (A) or valine (V), and/or glycine (G) at position 417 is replaced by serine (S) or alanine (A) or lysine (K) or valine (V) or arginine (R) or asparagine (N) or aspartic acid (D) or cysteine (C) or glutamine (Q) or glutamic acid (E ) or histidine (H) or isoleucine (I) or methionine (M) or phenyla
- screening for endogenous HPPD comprises at least one selected from the group consisting of L365K, F378A, G414A, G414V, G415A, G415V, G417S, G417A, G417K, G419W, F378A/G417A, G417V, G417R, Plants with one or more amino acid substitutions of G417N, G417D, G417C, G417Q, G417E, G417H, G417I, G417M, G417F, G417P, G417T, the amino acid positions are referenced to SEQ ID NO:1.
- plants are screened for endogenous HPPD (eg, expressed endogenous HPPD) mutated to the HPPD mutants described above in the invention.
- endogenous HPPD eg, expressed endogenous HPPD
- the present invention also provides a method of producing herbicide-resistant plants, comprising subjecting a population of said plants to physical or chemical mutagenesis, and screening for plants comprising or expressing the HPPD mutants of the present invention described above .
- a “herbicide-resistant plant” may refer to an endogenous HPPD mutagenized plant of the invention having enhanced resistance to HPPD-inhibiting herbicides, eg, enhanced 10 %, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or higher. Methods for determining resistance to HPPD-inhibiting herbicides are known in the art. Resistance can be readily determined by one skilled in the art for a specific plant and specific herbicide.
- the herbicide-resistant plants of the present invention are capable of at least 1 ⁇ mol/L, at least 1.5 ⁇ mol/L, at least 1.8 ⁇ mol/L, at least 2 ⁇ mol/L, at least 3 ⁇ mol/L, at least 5 ⁇ mol/L, at least 10 mol Normal growth was exhibited in the presence of herbicides (eg, HPPD-inhibiting herbicides such as mesotrione) at concentrations of /L or higher.
- herbicides eg, HPPD-inhibiting herbicides such as mesotrione
- the physical mutagenesis can be accomplished by radioactively irradiating the plant population (eg, irradiating plant seeds).
- the chemical mutagenesis can be accomplished by treating the plant population (eg, treating plant seeds) with ethyl methanesulfonate (EMS).
- EMS ethyl methanesulfonate
- the screening can be accomplished by sequencing the coding sequence of the endogenous HPPD.
- the present invention also provides a herbicide-resistant plant produced by the physical or chemical mutagenesis method of the present invention.
- the present invention also encompasses the progeny of said herbicide-resistant plants.
- the plants described in various aspects of the invention may be plants susceptible to HPPD inhibitors, including monocotyledonous or dicotyledonous plants.
- the plant is a crop plant, such as a monocotyledonous crop plant.
- suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, oats, Arabidopsis, ryegrass, ryegrass, wild soybean, soybean, and tobacco, among others.
- the plant is rice.
- the plant is maize.
- the plant is soybean.
- the plant is tobacco.
- the present invention provides a method of plant breeding, comprising crossing a first plant having herbicide resistance obtained by the above-described method of the present invention with a second plant not containing said herbicide resistance, thereby bringing The herbicide resistance is introduced into the second plant.
- the plants described in various aspects of the invention may be plants susceptible to HPPD inhibitors, including monocotyledonous or dicotyledonous plants.
- the plant is a crop plant, such as a monocotyledonous crop plant.
- suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, oats, Arabidopsis, ryegrass, ryegrass, wild soybean, soybean, and tobacco, among others.
- the plant is rice.
- the plant is maize.
- the plant is soybean.
- the plant is tobacco.
- Wild-type OsHPPD (amino acid sequence shown in SEQ ID NO: 1) was expressed and purified in pET-smt vector.
- circular PCR is used to design forward and reverse primers at the sites that need to be mutated. After PCR, transformation, sequencing and other steps, mutant plasmids with correct point mutations are obtained for the next experiment.
- Transform E. coli BL21 (DE3) competent cells with the mutant plasmid confirmed by sequencing (12-14h). Observe the turbidity and vigorous growth of the bacterial liquid cultured in a small amount of the test tube. Take 2 mL of bacterial liquid and inoculate it into a small triangular flask containing 120 mL of freshly prepared liquid LB medium, and expand the culture at 37°C and 220 rpm for 12 hours. The bacterial liquid in the small triangular flask was inoculated into the freshly prepared TB medium, and 10 mL of bacterial liquid was added to each 500 mL of TB medium.
- the expressed HPPD protein is tagged with 10 histidines, so it can be combined with nickel ions on the chromatography medium to achieve the purpose of separation from other impurities.
- the target protein adsorbed on the chromatographic medium can be eluted by using the free ligand solvent to complete the preliminary purification of the target protein.
- GE's model Superdex 200 increase molecular sieve was used for gel filtration chromatography purification.
- the protein sample after passing through the nickel column was concentrated with a Millipore tube, concentrated to a volume of 1ml, and transferred to a new 1.5mL EP tube.
- the pellet was removed by centrifugation at 13,000 rpm for 10 minutes at 4°C.
- the centrifuged protein was injected into the molecular sieve by the high-efficiency protein liquid-phase purification system AKTA purifier 10 for further purification and separation of the target HPPD protein, and then SDS-PAGE gel electrophoresis was performed to observe the size and purity of the HPPD protein.
- Example 4 Activity determination of enzyme reaction kinetics of OsHPPD, zmHPPD and gmHPPD proteins and identification of resistant mutants based on inhibition kinetics
- Figures 1-5 show the changes in the velocity V0 calculated from the measured absorbance values of the mutants under seven mesotrione concentration gradients. The values of these mutants are higher than those of the wild type, indicating that they have Herbicide-Mesotrione Resistance.
- Figure 6 there are 13 mutants whose Ki value is larger than that of the wild type at the amino acid G417 position. The larger the Ki value, the stronger the resistance of the mutants.
- rice HPPD mutants with double or triple mutations (containing amino acid substitutions F378A/G415A, F378A/G415V, F378A/G417K, F378A/G417R, F378A/G417V, G414V/G417K, F378A/G417A/G415A, F378A, respectively /G417K/G415V, numbered relative to SEQ ID NO: 1; their amino acid sequences are shown in SEQ ID NO: 48-55, respectively) also showed resistance to herbicides (Figure 7).
- the corn-derived HPPD mutants shown in Figure 8 (containing amino acid substitutions F373A/G412A, G409A, G412K, G412Q, G412R, respectively, numbered relative to SEQ ID NO: 9; or containing amino acid substitutions F378A/G417A, G414A, G417K, respectively, G417Q, G417R, numbered relative to SEQ ID NO: 1; their amino acid sequences are shown in SEQ ID NO: 38-42, respectively) and soybean-derived HPPD mutants (containing amino acid substitutions F386A/G425A, G422A, G425K, G425Q, G425R, respectively) , numbering relative to SEQ ID NO: 13; or respectively comprising amino acid substitutions F378A/G417A, G414A, G417K, G417Q, G417R, numbering relative to SEQ ID NO: 1; their amino acid sequences are shown in SEQ ID NO: 43-47
- the total genomic DNA was extracted from the transformed and regenerated rice leaves, and a small amount was used as a PCR amplification template.
- the sequences of the Ubi-1 promoter and HPPD on the expression vector were used to set primers before and after respectively to identify whether the genome was integrated with the expression vector.
- RNA of the plant with the integrated expression vector and reverse-transcribe it into cDNA, perform real-time fluorescent quantitative PCR (called quantitative RT-PCR or qRT-PCR) reaction, using ChamQTM Universal qPCR Master Mix reagent.
- quantitative RT-PCR quantitative RT-PCR
- qRT-PCR real-time fluorescent quantitative PCR
- the primers for the target gene and internal reference gene required for qRT-PCR were synthesized and designed, and qRT-PCR was performed according to the manufacturer's instructions.
- the target gene expression content of the experimental group relative to the control group was X experimental group/X control group.
- mesotrione stock solution was added to the rooting medium of rice to configure M6 solid medium containing different mesotrione concentration gradients (Table 1). Then, the rice seedlings overexpressing wild-type HPPD and wild-type rice seedlings were tested, and tissue culture seedlings with similar growth status and a plant height of about 6 cm from the growth point were selected and transferred to the medium with different mesotrione concentration gradients. Subculture, three seedlings per dish, 3 dishes per mesotrione concentration of overexpression and wild-type rice seedlings.
- the growth phenotype of the seedlings screened by mesotrione was observed: when the concentration of mesotrione in the medium was lower than OsW3, both wild-type and overexpressing rice seedlings grew normally; mesotrione When the concentration is higher than OsW3 and lower than OsW2, the newly grown young leaves of wild-type rice seedlings turn white, and the overexpression material grows normally; when the mesotrione concentration is higher than OsW2, the newly grown young leaves of the overexpression material turn white , while the leaves of wild-type rice seedlings turned white faster. Therefore, OsW2 was chosen as the screening concentration for the overexpression material.
- Table 1 Phenotypic identification of rice under different concentration gradients of mesotrione screening.
- the wild-type OsHPPD-CDS-WT sequence was cloned into the vector backbone of pBSE401 and expressed by the 35S promoter. Use circular PCR to design forward and reverse primers at the sites that need to be mutated. After PCR, transformation, sequencing and other steps, the point-mutated OsHPPD-CDS-G417K sequence was obtained. Initiate expression.
- Total genomic DNA was extracted from tobacco leaves, and a small amount was used as a template for PCR amplification.
- the sequences of the 35S promoter and HPPD on the expression vector were used to set up primers before and after, to identify whether the genome was integrated with the expression vector.
- RNA of the plant with the integrated expression vector and reverse-transcribe it into cDNA, perform real-time fluorescent quantitative PCR (called quantitative RT-PCR or qRT-PCR) reaction, using ChamQTM Universal qPCR Master Mix reagent.
- quantitative RT-PCR quantitative RT-PCR
- qRT-PCR real-time fluorescent quantitative PCR
- NtActin as the internal reference gene, synthesize and design primers for the target gene and internal reference gene required for qRT-PCR, and perform qRT-PCR according to the manufacturer's instructions. .
- the target gene expression content of the experimental group relative to the control group was X experimental group/X control group.
- tobacco rooting media with different mesotrione concentration gradients were prepared (Table 3). Then, the wild-type HPPD-overexpressing tobacco and wild-type tobacco tissue culture seedlings with consistent growth status were selected and transferred to the medium supplemented with mesotrione for subculture. After a period of screening and cultivation, young tobacco leaves with weak resistance gradually turned white. Therefore, the lowest mesotrione concentration that tobacco overexpressing wild-type OsHPPD cannot tolerate was selected as the tobacco screening concentration.
- Table 3 Phenotypic identification of tobacco screened at different mesotrione concentrations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Dentistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (27)
- 一种HPPD突变体或其功能性片段,其相对于野生型HPPD在选自第417、365、378、414、415、或419位的一或多个位置处具有氨基酸突变例如氨基酸取代,所述氨基酸位置参考SEQ ID NO:1。
- 权利要求1的HPPD突变体或其功能性片段,其相对于野生型HPPD在选自以下的位置处具有氨基酸突变例如氨基酸取代,所述氨基酸位置参考SEQ ID NO:1:i)第378和415位;ii)第378和417位;iii)第414和417位;或iv)第378、415和417位。
- 权利要求1或2的HPPD突变体或其功能性片段,所述野生型HPPD包含SEQ ID NO:1-13之一的氨基酸序列。
- 权利要求1-3中任一项的HPPD突变体或其功能性片段,所述HPPD突变体或其功能性片段在植物中表达时,能够赋予所述植物对除草剂的抗性。
- 权利要求4的HPPD突变体或其功能性片段,所述除草剂选自吡唑类化合物,例如苯吡唑草酮、磺酰草吡唑、酸苯偶氮吡胺;三酮类化合物,例如磺草酮、硝磺草酮、特波三酮、特糠酯酮、双环吡喃酮、苯并双环酮;异噁唑类化合物,例如异噁唑草酮;二酮腈类化合物,例如2-氰基-3-环丙基-1-(2-甲基磺酰基-4-三氟甲基苯基)-丙烷-1,3-二酮和2-氰基-1-[4-(甲基磺酰基)-2-三氟甲基苯基]-3-(1-甲基环丙基)丙烷-1,3-二酮;和二苯酮类化合物,或它们的任意组合。
- 权利要求1-5中任一项的HPPD突变体或其功能性片段,其中相对于野生型HPPD,所述HPPD突变体或其功能性片段包含选自G417K、G417S、G417A、G419W、G417V、G417R、G417N、G417D、G417C、G417Q、G417E、G417H、G417I、G417M、G417F、G417P、G417T、L365K、F378A、G414A、G414V、G415A、G415V的一个或多个氨基酸取代,所述氨基酸位置参考SEQ ID NO:1。
- 权利要求6的HPPD突变体或其功能性片段,其中相对于野生型HPPD,所述HPPD突变体或其功能性片段包含选自以下的氨基酸取代i)F378A和G415A;ii)F378A和G415V;iii)F378A和G417K;iv)F378A和G417R;v)F378A和G417V;vi)F378A和G417A;vii)G414V和G417K;viii)F378A、G415A和G417A;或ix)F378A、G415V和G417K;其中所述氨基酸位置参考SEQ ID NO:1。
- 权利要求1-7中任一项的HPPD突变体或其功能性片段,所述HPPD突变体包含SEQ ID NO:14-55中任一所示的氨基酸序列。
- 一种核酸,其包含编码权利要求1-8中任一项的HPPD突变体或其功能性片段的核苷酸序列。
- 一种表达盒,其包含与调控序列可操纵地连接的编码权利要求1-8中任一项的HPPD突变体或其功能性片段的核苷酸序列。
- 一种表达构建体,其包含权利要求10的表达盒。
- 一种通过转基因产生除草剂抗性植物的方法,包括将权利要求9的核酸、权利要求10的表达盒和/或权利要求11的表达构建体导入所述植物中。
- 一种产生除草剂抗性植物的方法,所述方法包括靶向修饰植物的内源HPPD编码序列,由此导致所述内源HPPD在选自第417、365、378、414、415或419位的一或多个位置处的氨基酸突变,所述氨基酸位置参考SEQ ID NO:1。
- 权利要求13的方法,其中所述靶向修饰导致所述内源HPPD包含选自G417K、G417S、G417A、G419W、G417V、G417R、G417N、G417D、G417C、G417Q、G417E、G417H、G417I、G417M、G417F、G417P、G417T、F378A/G417A、L365K、F378A、G414A、G414V、G415A、G415V的一个或多个氨基酸取代,所述氨基酸位置参考SEQ ID NO:11。
- 权利要求13或14的方法,其中所述靶向修饰导致权利要求1-8中任一项所述的HPPD突变体。
- 权利要求13-15中任一项的方法,其中通过基因编辑或同源重组来进靶向修饰所述内源HPPD的编码序列。
- 权利要求16的方法,其中所述基因编辑是碱基编辑(base editing)或引导编辑(prime editing)。
- 一种产生除草剂抗性植物的方法,包括对所述植物的群体进行物理诱变或化学诱变,并且筛选内源HPPD至少在选自第417、365、378、414、415或419位的一或多个位置,例如1、2、3、4、5或6个位置处包含氨基酸突变的植物,其中所述氨基酸位置参考SEQ ID NO:1。
- 权利要求18的方法,其中筛选内源HPPD包含至少选自G417K、G417S、G417A、G419W、G417V、G417R、G417N、G417D、G417C、G417Q、G417E、G417H、G417I、G417M、G417F、G417P、G417T、F378A/G417A、L365K、F378A、G414A、G414V、G415A、G415V的一个或多个氨基酸取代的植物,所述氨基酸位置参考SEQ ID NO:1。
- 权利要求18或19的方法,其中筛选包含或表达权利要求1-8中任一项所述的HPPD突变体的植物。
- 权利要求18-20中任一项的方法,其中所述物理诱变包括通过放射性照射所述植物群体,所述化学诱变包括通过用甲基磺酸乙酯(EMS)处理所述植物群体。
- 权利要求12-21中任一项的方法,其中所述植物包括单子叶植物或双子叶植物,优选地,所述植物是作物植物,例如单子叶作物植物。
- 权利要求22的方法,其中所述植物选自水稻、小麦、大麦、高粱、玉米、燕麦、拟南芥、硬直黑麦草、旱雀麦、野生大豆、大豆和烟草。
- 一种除草剂抗性植物或其后代,其包含或表达权利要求1-8中任一项所述的HPPD突变体或其功能性片段,或其通过权利要求12-21中任一项的方法产生。
- 权利要求24的除草剂抗性植物或其后代,其中所述植物包括单子叶植物或双子叶植物,优选地,所述植物是作物植物,例如单子叶作物植物。
- 权利要求25的除草剂抗性植物或其后代,其中所述植物选自水稻、小麦、大麦、高粱、玉米、燕麦、拟南芥、硬直黑麦草、旱雀麦、野生大豆、大豆和烟草。
- 权利要求1-8中任一项所述的HPPD突变体或其功能性片段、权利要求9的核酸、权利要求10的表达盒和/或权利要求11的表达构建体在产生除草剂抗性植物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180074442.9A CN116724119A (zh) | 2020-12-17 | 2021-12-17 | 除草剂抗性植物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011493546.7 | 2020-12-17 | ||
CN202011493546 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022127894A1 true WO2022127894A1 (zh) | 2022-06-23 |
Family
ID=82058943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/139052 WO2022127894A1 (zh) | 2020-12-17 | 2021-12-17 | 除草剂抗性植物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116724119A (zh) |
AR (1) | AR124409A1 (zh) |
WO (1) | WO2022127894A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102348802A (zh) * | 2009-01-22 | 2012-02-08 | 先正达参股股份有限公司 | 突变体羟基苯丙酮酸双加氧酶多肽及其使用方法 |
CN103237894A (zh) * | 2010-08-13 | 2013-08-07 | 先锋国际良种公司 | 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法 |
CN108866092A (zh) * | 2017-05-11 | 2018-11-23 | 中国科学院遗传与发育生物学研究所 | 抗除草剂基因的产生及其用途 |
CN110616203A (zh) * | 2018-06-04 | 2019-12-27 | 青岛清原化合物有限公司 | 突变型对羟苯基丙酮酸双氧化酶、其编码核酸以及应用 |
US20200063155A1 (en) * | 2017-03-07 | 2020-02-27 | BASF Agricultural Solutions Seed US LLC | Hppd variants and methods of use |
CN113574173A (zh) * | 2019-09-17 | 2021-10-29 | 北京大北农生物技术有限公司 | 突变的羟基苯丙酮酸双加氧酶多肽、其编码基因及用途 |
-
2021
- 2021-12-17 WO PCT/CN2021/139052 patent/WO2022127894A1/zh active Application Filing
- 2021-12-17 CN CN202180074442.9A patent/CN116724119A/zh active Pending
- 2021-12-17 AR ARP210103554A patent/AR124409A1/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102348802A (zh) * | 2009-01-22 | 2012-02-08 | 先正达参股股份有限公司 | 突变体羟基苯丙酮酸双加氧酶多肽及其使用方法 |
CN103237894A (zh) * | 2010-08-13 | 2013-08-07 | 先锋国际良种公司 | 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法 |
US20200063155A1 (en) * | 2017-03-07 | 2020-02-27 | BASF Agricultural Solutions Seed US LLC | Hppd variants and methods of use |
CN108866092A (zh) * | 2017-05-11 | 2018-11-23 | 中国科学院遗传与发育生物学研究所 | 抗除草剂基因的产生及其用途 |
CN110616203A (zh) * | 2018-06-04 | 2019-12-27 | 青岛清原化合物有限公司 | 突变型对羟苯基丙酮酸双氧化酶、其编码核酸以及应用 |
CN113574173A (zh) * | 2019-09-17 | 2021-10-29 | 北京大北农生物技术有限公司 | 突变的羟基苯丙酮酸双加氧酶多肽、其编码基因及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116724119A (zh) | 2023-09-08 |
AR124409A1 (es) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11447785B2 (en) | Method for base editing in plants | |
US20220267788A1 (en) | Creation of herbicide resistant gene and use thereof | |
US11820990B2 (en) | Method for base editing in plants | |
JP2021506232A (ja) | Ppo除草剤耐性のための方法及び組成物 | |
KR20200078685A (ko) | 부위-특이적인 뉴클레오티드 치환을 통해 글리포세이트-내성 벼를 수득하는 방법 | |
BG61276B1 (bg) | Резистентни на имидазолидинон мутанти на ензими ацетохидрокси синтетаза | |
WO2021032155A1 (zh) | 一种碱基编辑***和其使用方法 | |
CN111818794A (zh) | 增加营养物利用效率的方法 | |
TW201825678A (zh) | 用於建立靶向重組及中斷性狀之間之連鎖的方法及組成物 | |
CN110621154A (zh) | 用于植物的除草剂耐受性的方法和组合物 | |
CN112805385B (zh) | 基于人apobec3a脱氨酶的碱基编辑器及其用途 | |
CN110885365A (zh) | Ataf2蛋白及其相关生物材料在调控植物对橡胶树白粉菌的抗病性中的应用 | |
WO2022127894A1 (zh) | 除草剂抗性植物 | |
WO2021047656A1 (zh) | 除草剂抗性植物 | |
US20230227835A1 (en) | Method for base editing in plants | |
CN114516906B (zh) | 玉米与菌根真菌共生相关蛋白及其编码基因与应用 | |
CN115216488B (zh) | 创制水稻大长粒型新种质或大长粒型矮杆新种质的方法及其应用 | |
WO2023115030A2 (en) | Lodging resistance in eragrostis tef | |
WO2022144877A1 (en) | Herbicide resistant cannabis plant | |
WO2024077110A2 (en) | Uorf::reporter gene fusions to select sequence changes to gene edit into uorfs to regulate ascorbate genes | |
KR20230139656A (ko) | 반수체 식물을 유도하는 pPLAⅡγ 유전자 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21905820 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180074442.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21905820 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21905820 Country of ref document: EP Kind code of ref document: A1 |